Good communication skills are essential for physicians because explaining concepts like cardiovascular disease and stroke risk to patients is part of the art of medicine. In this segment, the panelists discuss strategies for communicating risk and talk about using the ASCVD Risk Estimator tool in practice.
Although the guidelines call for higher doses of statin therapy in patients with a history of cardiovascular disease, patients who are not at high-risk may benefit from a lower starting dose. The panelists agree that physicians should discuss the pros and cons of this approach with their patients.
Friday could be a big day for cardiologists. The FDA is due to rule July 24 on what could be the first available PCSK9 inhibitor, one of a new class of cholesterol-lowering agents meant to help patients who cannot get their LDL levels low enough with statins. New York City cardiologist David Vorchheimer, MD. talks about his hopes for the new drugs, and a few concerns
A proportion of patients with the human immunodeficiency virus (HIV) are able to naturally control its progression – known as nonprogressors. While ‘how?’ remains a primary question, a new discovery may be on the right track to explaining it.
When it comes to statin therapy, what is the proper way to prescribe them? Should physicians prescribe to a target or should they default to a high-intensity statin? The panelists provide several interesting perspectives on these issues.